Immunotoxin in Treating Patients With Leukemia or Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

1996-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Immunotoxins can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.

PURPOSE: Phase I trial to study the effectiveness of LMB-2 immunotoxin in treating patients who have leukemia or lymphoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors

NCT00019435

Bladder Cancer Breast Cancer Colorectal Cancer +4 more

COMPLETED PHASE1

LMB-2 to Treat Hairy Cell Leukemia

NCT00321555

Hairy Cell Leukemia

COMPLETED PHASE2

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas

NCT00080535

Lymphoma T-Cell Cutaneous

COMPLETED PHASE2

LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer

NCT00005858

Bladder Cancer Breast Cancer Colorectal Cancer +3 more

COMPLETED PHASE1

LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery

NCT00295958

Melanoma (Skin) Non-melanomatous Skin Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Assess the therapeutic efficacy and toxicity of the recombinant immunotoxin LMB-2, an anti-Tac murine monoclonal antibody fragment conjugated to a truncated portion of Pseudomonas exotoxin, in patients with Tac-expressing leukemias and lymphomas.
* Define the pharmacokinetics of LMB-2, including the terminal elimination serum half-life, area under the curve, and volume of distribution.
* Evaluate, in a preliminary manner, the immunogenicity of LMB-2 in these patients.
* Determine the effect of LMB-2 on various components of the circulating cellular immune system.

OUTLINE: This is a dose escalation study.

Patients receive LMB-2 immunotoxin IV over 30 minutes on days 1, 3, and 5. Treatment repeats every 15-21 days for up to 10 courses in the absence of disease progression, neutralizing antibodies, or unacceptable toxicity.

Cohorts of 3-6 patients each receive escalating doses of LMB-2 immunotoxin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 patient experiences dose limiting toxicity.

PROJECTED ACCRUAL: A maximum of 40 patients will be accrued for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leukemia Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LMB-2 immunotoxin

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* B-cell non-Hodgkin's lymphoma (NHL) of any histology

* Indolent stages II-IV NHL

* Failed at least 1 standard therapy
* Disease symptomatic and requiring treatment
* Aggressive NHL

* Relapsed after standard chemotherapy
* Ineligible for or refused salvage chemotherapy or BMT
* Chronic lymphocytic leukemia (CLL)

* Rai stages III and IV or Binet stage C
* Failed standard therapy and at least 1 salvage chemotherapy
* Primary B-cell prolymphocytic leukemia or prolymphocytic transformation of CLL

* Failed standard therapy and at least 1 salvage chemotherapy
* Hairy cell leukemia

* Failed standard and salvage chemotherapy
* Ineligible for or refused further salvage chemotherapy or BMT
* Acute myelogenous leukemia

* Failed standard chemotherapy
* Ineligible for or refused salvage chemotherapy or BMT
* Stages II-IV Hodgkin's disease

* Failed standard chemotherapy
* Ineligible for curative salvage radiotherapy or chemotherapy
* Ineligible for or refused BMT
* Patients with leukemias or lymphomas not easily classified in above categories who have failed standard therapy and are ineligible for or have refused bone marrow transplant
* Evidence of interleukin-2 receptor-alpha (IL2Ra) expression by one of the following:

* Greater than 10% of malignant cells reactive with anti-Tac by immunohistochemistry
* Greater than 10% of malignant cells from a particular site positive by FACS
* Greater than 400 IL2Ra sites per malignant cell by radiolabeled anti-Tac binding
* Soluble IL2Ra level greater than 1,000 U/mL (normal geometric mean 235, with 95% confidence levels of 112-502 U)
* Hodgkin's disease with measurable disease not amenable to biopsy
* No CNS disease requiring treatment

* Malignant cells in CSF allowed if judged not to represent clinically significant leukemic or lymphomatous meningitis (as in CSF contamination by blood)

PATIENT CHARACTERISTICS:

Age:

* 18 and over

Performance status:

* Karnofsky 50-100%

Life expectancy:

* Greater than 2 months

Hematopoietic:

* Absolute neutrophil count greater than 1,000/mm3\*
* Platelet count greater than 50,000/mm3\* NOTE: \*nonleukemic patients

Hepatic:

* AST and ALT less than 5 times normal

Renal:

* Creatinine less than 2.0 mg/dL OR
* Creatinine clearance greater than 50 mL/min

Pulmonary:

* FEV1, TLC, and DLCO greater than 50% of predicted if pulmonary or mediastinal involvement with tumor greater than one third of total thoracic diameter

Other:

* HIV negative
* Not pregnant
* Fertile patients must use effective contraception
* Serum must neutralize no more than 75% LMB-2 in tissue culture

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* See Disease Characteristics
* At least 3 weeks since prior interferon

Chemotherapy:

* See Disease Characteristics
* At least 3 weeks since prior cytotoxic chemotherapy
* At least 3 weeks since prior retinoids
* No concurrent chemotherapy

Endocrine therapy:

* No concurrent corticosteroids unless begun at least 3 weeks prior to entry and dose not increased during 3 weeks prior to entry

Radiotherapy:

* See Disease Characteristics
* At least 3 weeks since prior whole-body electron beam radiotherapy
* Other radiotherapy allowed within 3 weeks of entry provided less than 10% of marrow irradiated and measurable disease exists outside radiation port

Surgery:

* Not specified

Other:

* See Disease Characteristics
* At least 3 weeks since any prior systemic therapy
* No other concurrent investigational agents

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No